Press Releases
Corbus Pharmaceuticals Announces $27.2 Million Registered Direct Offering
Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
Corbus Pharmaceuticals to Host Research and Development Day on March 13, 2017
Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union
Corbus Pharmaceuticals Announces Completion of Phase 2 Study of JBT-101 (Resunab) for the Treatment of Cystic Fibrosis
Corbus Pharmaceuticals Announces NASDAQ Closing Bell Ceremony
Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis
Corbus Pharmaceuticals Reports Positive Topline Results Showing Clear Signal of Clinical Benefit with Resunab (JBT-101) in Phase 2 Study in Systemic Sclerosis
Corbus Pharmaceuticals Reports 2016 Third Quarter Financial Results and Provides Business Update
Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union
Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis
Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
Corbus Pharmaceuticals to Present at the Jefferies Cystic Fibrosis Summit
Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis
Corbus Pharmaceuticals Reports 2016 Second Quarter Financial Results and Provides Business Update
Corbus Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016
Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 22, 2016
Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis
Corbus Pharmaceuticals Completes $15 Million Registered Direct Offering
Corbus Pharmaceuticals Announces $15 Million Registered Direct Offering
Corbus Pharmaceuticals Reports 2016 First Quarter Financial Results and Provides Business Update
Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis
Corbus Pharmaceuticals Announces Addition of Phase 2 Clinical Protocol for Resunab Treatment of Systemic Lupus Erythematosus to FDA IND
Corbus Pharmaceuticals Reports 2015 Financial Results and Provides 2016 Business Update
